

#### GALT Antibody (C-term) Blocking Peptide Synthetic peptide

Catalog # BP6880b

### Specification

## GALT Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>P07902</u>

### GALT Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 2592

**Other Names** Galactose-1-phosphate uridylyltransferase, Gal-1-P uridylyltransferase, UDP-glucose--hexose-1-phosphate uridylyltransferase, GALT

Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP6880b>AP6880b</a> was selected from the C-term region of human GALT. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### **Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### GALT Antibody (C-term) Blocking Peptide - Protein Information

Name GALT

**Function** Plays an important role in galactose metabolism.

# GALT Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

# GALT Antibody (C-term) Blocking Peptide - Images



### GALT Antibody (C-term) Blocking Peptide - Background

Galactose-1-phosphate uridyl transferase (GALT) catalyzes the second step of the Leloir pathway of galactose metabolism, namely the conversion of UDP-glucose + galactose-1-phosphate to glucose-1-phosphate + UDP-galactose. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet.

#### GALT Antibody (C-term) Blocking Peptide - References

Leslie, N.D., et.al., Genomics 14 (2), 474-480 (1992)